Neurodevelopmental outcomes (moderate/severe language delay at 18 to 24 months) · preterm infants
Very early treatment showed no clear difference in neurodevelopmental outcomes (moderate/severe language delay at 18 to… compared with expectant management (low certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation All participants · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).
1 finding from 1 review
Dental caries: prevalence of moderate to extensive caries (ICDAS 3-6) · Dentate adults (aged 18 years and older) receiving dental check-ups in UK general dental practices (regular attenders)
Clinical examination with risk-based recall showed no clear difference in dental caries: prevalence of moderate to extensive caries (ICDAS 3-6) compared with clinical examination with 6-month recall (moderate certainty).
1 finding from 1 review
Dental caries: prevalence of moderate to extensive caries (ICDAS 3-6) · Dentate adults (aged 18 years and older) receiving dental check-ups in UK general dental practices (regular attenders)
Clinical examination with risk-based recall showed no clear difference in dental caries: prevalence of moderate to extensive caries (ICDAS 3-6) compared with clinical examination with 24-month recall (moderate certainty).
1 finding from 1 review
Beck Depression Inventory (BDI); higher score means more depression · people with ESKD
Exercise showed no clear difference in depression (any severity, including mild, moderate and severe… compared with usual care (moderate certainty).
1 finding from 1 review
Depressive symptoms · people with ESKD
Cognitive‐behavioural therapy showed no clear difference in depression (any severity, including mild, moderate and severe… compared with usual care (moderate certainty).
1 finding from 1 review
Depressive symptoms · people with ESKD
Relaxation techniques showed no clear difference in depression (any severity, including mild, moderate and severe… compared with usual care (moderate certainty).
1 finding from 1 review
Beck Depression Inventory (BDI); higher score means more depression · people with ESKD
It is very uncertain whether spiritual practice changes depression (any severity, including mild, moderate and severe… compared with usual care (very low certainty).
1 finding from 1 review